Search
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] … Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEsculin
go.drugbank.com/drugs/DB13155ApprovedThese are carbohydrate derivatives in which a sugar group is bonded through its anmoeric carbonA to another group via a C-, S-,N-,O-, or Se- glycosidic bond. … Esculin belongs to the family of Glycosyl Compounds.
Synonyms: Esculetin 6-O-glucoside, 6,7-Dihydroxycoumarin-6-O-glucosidePoloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … Composed of two hydrophilic side-chains attached to a hydrophobic center core [A27218], its average molecular weight is 8400 Daltons.
Categories: Compounds used in a research, industrial, or household settingFlotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational[A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … Flotufolastat F-18 is a diastereoisomer of <sup>18</sup>F-rhPSMA-7, and compared to the other diastereoisomers of this compound, flotufolastat F-18 has a faster clearance from blood pool, liver, and kidney
Amineptine
go.drugbank.com/drugs/DB04836ApprovedIllicitWithdrawnThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeReserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnThe FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942] … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Categories: Antihypertensive Agents Indicated for HypertensionAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]
Medical air
go.drugbank.com/drugs/DB09337ApprovedInvestigationalVet approvedMedical air is supplied by a special air compressor to patient care areas using clean outside air.
Human papillomavirus type 6 L1 capsid protein antigen
go.drugbank.com/drugs/DB10299ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTIONAPL-9
go.drugbank.com/drugs/DB16460InvestigationalIt shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.
Categories: Experimental Unapproved Treatments for COVID-19